Alltrna Appoints New Chief Medical Officer
Alltrna, a pioneering company in the field of transfer RNA (tRNA) biology, has officially announced the appointment of Dr. Nerissa Kreher as its Chief Medical Officer (CMO). This move is aimed at advancing their cutting-edge tRNA medicines targeted at rare diseases. Dr. Kreher brings with her a wealth of experience in drug development for rare conditions, including extensive involvement in clinical and regulatory strategies tailored for both early and late-stage clinical programs.
Driving Innovation in Therapeutics
The CEO of Alltrna, Michelle C. Werner, expressed her enthusiasm for Dr. Kreher joining the leadership team. "We are excited to have Nerissa on board as we move our first tRNA development candidates into clinical settings, especially focusing on liver Stop Codon Disease. Her proven capabilities in advancing innovative therapies and navigating the complexities of regulatory pathways are crucial for our mission to deliver transformative treatments to those who need them the most," she stated.
Dr. Kreher's Vision for Alltrna
In her new role, Dr. Kreher has expressed immense enthusiasm for the potential of Alltrna's tRNA platform. "Being part of Alltrna at this pivotal moment is truly an honor. Our work with tRNA technology opens doors to developing novel therapeutics for both rare and underserved diseases. I am eager to collaborate with this dynamic team to bring our first tRNA medicines to life," she commented.
Impressive Background in Rare Disease Therapies
Dr. Kreher's impressive career spans over several leadership roles in both private and public biotech companies, with a strong focus on biotechnology and rare diseases. She is particularly known for her contributions to the development and launch of therapies targeting conditions in neuromuscular and metabolic fields, as well as lysosomal storage disorders.
Recent Achievements and Contributions
Before her current appointment at Alltrna, Dr. Kreher served as CMO at Entrada Therapeutics, where she was at the forefront of shaping clinical and regulatory strategies while overseeing medical affairs. Her previous positions include pivotal CMO roles at Tiburio Therapeutics and AVROBIO, overseeing clinical development for various gene therapy initiatives. Dr. Kreher also has an impressive history at Zafgen, where she was the Global Head of Clinical and Medical Affairs, and played a significant role in the $1 billion acquisition of Enobia Pharma by Alexion Pharmaceuticals.
Educational Excellence and Credentials
Dr. Kreher is not only a skilled physician executive but also a certified Pediatric Endocrinologist recognized by the American Board of Pediatrics. She acquired her medical degree from East Carolina University’s School of Medicine and has mastered Clinical Research at Indiana University. Additionally, she completed an Executive MBA program at Northeastern University.
About Alltrna
Alltrna specializes in unlocking the potential of tRNA biology to combat various diseases. Leveraging advanced AI and machine learning tools, the company focuses on developing and delivering diverse, programmable therapeutic molecules. Alltrna aims to pioneer a novel tRNA medicine that addresses premature stop codons, significantly impacting treatment across a spectrum of diseases stemming from similar genetic mutations. Founded in 2018 by Flagship Pioneering, Alltrna is positioned to play a crucial role in the evolution of rare disease therapies.
Media Inquiries
For media inquiries, please contact:
Jessica Yingling, Ph.D., Little Dog Communications Inc., +1.858.344.8091
Josephine Zorbo, Ph.D., Flagship Pioneering.
Frequently Asked Questions
Who is Dr. Nerissa Kreher?
Dr. Nerissa Kreher is the newly appointed Chief Medical Officer at Alltrna, bringing extensive experience in rare disease drug development.
What is Alltrna's primary focus?
Alltrna focuses on advancing tRNA therapeutics to treat rare diseases through innovative drug development.
Why is Dr. Kreher's appointment important?
Her expertise in clinical development and regulatory strategy will accelerate Alltrna's mission to deliver new therapies to patients.
What is the significance of tRNA medicines?
tRNA medicines have the potential to rectify genetic errors that cause diseases, offering hope to patients with rare genetic conditions.
How will Alltrna use AI in its operations?
Alltrna utilizes AI and machine learning to develop programmable therapeutic molecules with broad applications across various diseases.
